ProfileGDS5678 / 1435811_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 88% 88% 88% 88% 89% 87% 88% 88% 86% 87% 87% 88% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9157789
GSM967853U87-EV human glioblastoma xenograft - Control 26.892988
GSM967854U87-EV human glioblastoma xenograft - Control 36.8497988
GSM967855U87-EV human glioblastoma xenograft - Control 46.9969788
GSM967856U87-EV human glioblastoma xenograft - Control 56.964188
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8454389
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5212387
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7258388
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8012788
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5148486
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.6221287
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.810787
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8389188
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1718890